Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 378

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 378
---
 Operating lease liabilities, current                                   |     |                    |   769,092 |   |     |   |   672,374 |   |
| Operating lease liabilities, non-current                               |     |                    | 1,575,499 |   |     |   | 2,344,590 |   |
| Total operating lease liabilities                                      |     | $                  | 2,344,591 |   |     | $ | 3,016,964 |   |
| Weighted-average remaining lease term of operating leases (in years)   |     |                    |      2.75 |   |     |   |      3.75 |   |
| Weighted-average discount rate for operating leases                    |     |                    |      9.60 | % |     |   |      9.60 | % |

F-60 CERo Therapeutics, Inc. Notes to Financial Statements

The interest expense related to leases was $
and $ for years ended December 31, 2023 and 2022, respectively.

| Year ending December 31: 
 2024                     |     | Operating 
 Leases    |   961,218 |   |
|:-------------------------|:----|:----------|----------:|:--|
| 2025                     |     |           |   990,055 |   |
| 2026                     |     |           |   726,394 |   |
| Total lease payments     |     |           | 2,677,667 |   |
| Less imputed interest    |     |           |  (333,076 | ) |
| Total lease liabilities  |     | $         | 2,344,591 |   |

NOTE 7 – CONVERTIBLE PREFERRED STOCK

The Company had shares of capital stock
authorized as of December 31, 2023 and 2022, consisting of shares of common stock and shares of convertible
preferred stock. All classes of the Company’s stock have a par value of $. On February 14, 2024, on the close of the business
combination (the “Business Combination”), pursuant to the Business Combination Agreement, dated as of June 4, 2023, as amended
from time to time (as amended, the “Business Combination Agreement”) by and among the Company, Phoenix Biotech Acquisition
Corp. (“PBAX”) and PBCE Merger Sub, Inc. (“Merger Sub”), the outstanding convertible preferred stock